2020 TTF EGFR SESSION QA PANEL SRT with Osimertinib (Tagrisso) First Line, Stable Disease

dbrock's picture
EGFR Session Question & Answer Panel - Using Stereotactic Radio Therapy (SRT) with Osimertinib (Tagrisso) First Line or During Stable Disease
Jared Weiss, MD, Faculty and Board Vice President
We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum.

This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.

In this video from the EGFR Breakout Session, Drs. Jared Weiss and Zofia Piotrowska answer questions from attendees of the event.

For this video, the docs discuss using stereotactic radio therapy with (SRT) with Osimertinib (Tagrisso) for first line or during stable disease.

 

We thank our sponsors for their support of this event! AstraZeneca, Lilly, Novartis, Takeda, Foundation Medicine, Boehringer Ingelheim, Blueprint Medicines and Genentech

Access to the full agenda can be found here: https://bit.ly/39131em

Full bios for attending faculty can be found here: https://bit.ly/2M0FVLH

 

To join the conversation, visit https://cancergrace.org/forum.

Video Language: 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation